Major shareholder announcement

Orphazyme A/SCompany announcement        No. 19/2021Company Registration No. 32266355

Copenhagen, Denmark, June 24, 2021 – Orphazyme A/S (ORPHA.CO; ORPH) (“the Company”), a late-stage biopharmaceutical company pioneering the heat shock protein response for the treatment of rare diseases, hereby announces the receipt of notification pursuant to Section 38 of the Danish Capital Markets Act from Aescap Venture Management B.V, that as of June 16, 2021, Aescap Venture Management B.V indirectly holds shares corresponding to less than 5% of the total share capital and voting rights in the Company.

For additional information, please contact

Orphazyme A/S

Anders Vadsholt, CFO                +45 28 98 90 55

About Orphazyme A/SOrphazyme is a late-stage biopharmaceutical company pioneering the heat shock protein response for the treatment of rare diseases. The company is harnessing amplification of heat shock proteins (or HSPs) in order to develop and commercialize novel therapeutics for diseases caused by protein misfolding, protein aggregation, and lysosomal dysfunction. Arimoclomol, the company’s lead candidate, is in clinical development for rare diseases including Niemann-Pick disease type C (NPC) and Gaucher disease. Orphazyme is headquartered in Denmark and has operations in the U.S. and Switzerland. Orphazyme’s shares are listed on Nasdaq U.S. (ORPH) and Nasdaq Copenhagen (ORPHA.CO).

Attachment

• 19-2021 Major shareholder announcement

You May Also Be Interested In

• BioSyent to Attend Planet MicroCap Showcase
• Baker Hughes Company Announces First-Quarter 2024 Results
• First Quantum Minerals Reports First Quarter 2024 Results